An interventional study of K101 nail solution in Onychomycosis, sponsored by Moberg Pharma AB. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-06-26.
Sponsored by Moberg Pharma AB · Not applicable and Interventional
The purpose of this study is to further evaluate and document early visible effects on nail appearance of topical K101.
147 studies on the registry are indexed under Onychomycosis; 13 are open to participants now.
This study's enrollment of 75 is above the median of 56 across 134 interventional studies indexed under Onychomycosis.
Browse Onychomycosis studies →Moberg Pharma AB is the lead sponsor of 14 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria
Proportion of patients experiencing at least some improvement of the target nail (scoring 2 or more according to Global Assessment Scale) after 8 weeks treatment.
No study locations are listed for this record.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Moberg Pharma AB